Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Processa Pharmaceuticals, Inc. - Common Stock
(NQ:
PCSA
)
0.3632
-0.0261 (-6.70%)
Streaming Delayed Price
Updated: 1:52 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Processa Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
TOMI Environmental (NASDAQ: TOMZ) | Listeria in Packaged Meals – A Public Health Alert! More Stocks Inside
October 07, 2025
Via
AB Newswire
Topics
Death
Lawsuit
Product Recall
Peraso Inc. (NASDAQ: PRSO) Signals Turnaround – Reports Financials August 11, 2025 – More Stocks Inside
August 07, 2025
Via
AB Newswire
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
August 07, 2025
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 18, 2025
Via
ACCESS Newswire
Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
June 17, 2025
Via
AB Newswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
October 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
September 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
August 28, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
August 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
July 30, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
July 17, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
June 11, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
May 06, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
April 30, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
April 11, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
March 25, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
February 02, 2024
Via
Investor Brand Network
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
January 26, 2024
Via
Investor Brand Network
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
January 26, 2024
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
January 25, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
January 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
January 18, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
January 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
December 19, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Gains Helpful Guidance on Overall Design of NGC-Cap Phase 2 Study
December 13, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in December MedInvest Oncology Investor Conference
November 30, 2023
Via
Investor Brand Network
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.